Skip to main
CRSP
CRSP logo

CRISPR Therapeutics (CRSP) Stock Forecast & Price Target

CRISPR Therapeutics (CRSP) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 25%
Hold 31%
Sell 6%
Strong Sell 0%

Bulls say

CRISPR Therapeutics is positioned positively in the gene editing space, particularly due to its first approved drug, Casgevy, which addresses significant unmet medical needs in sickle-cell disease and transfusion-dependent beta-thalassemia. The revitalization of large-cap pharma interest in gene editing platforms, as evidenced by recent acquisitions and clinical advancements from competitors, underscores a growing market potential for CRISPR's innovative technology across various therapeutic areas, including immuno-oncology and cardiometabolic diseases. The company's strategy of targeting well-validated diseases and exploring additional applications of its CRISPR/Cas9 platform supports a favorable outlook on its long-term growth prospects and market positioning.

Bears say

The analysis reflects a negative outlook for CRISPR Therapeutics, primarily based on the assumption that sales of its approved drug, Casgevy, may not accelerate as anticipated, leading to a potential 30% downside from the company's base case valuation. Key risks highlighted include delays in advancing critical drug candidates through trials, with only a 30% probability of approval for CTX112 and a mere 20% for both CTX320 and CTX310, alongside concerns over generating favorable clinical data. Additionally, the prospect of long-term dilution and challenges in demonstrating the safety and efficacy of several drug candidates, such as CTX112 and CTX320, exacerbate the uncertainty surrounding the company's financial future.

CRISPR Therapeutics (CRSP) has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 25% recommend Buy, 31% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CRISPR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CRISPR Therapeutics (CRSP) Forecast

Analysts have given CRISPR Therapeutics (CRSP) a Buy based on their latest research and market trends.

According to 16 analysts, CRISPR Therapeutics (CRSP) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $72.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $72.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CRISPR Therapeutics (CRSP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.